NET ASSET VALUE – 28 February 2026
On the 28 February 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,281 million and NAV per share was SEK 42.36. Return on NAV per share in the month was -0.11%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 50% | 272 | 3.51 | 8.3% |
| Empros Pharma | 79% | 204 | 2.64 | 6.2% |
| Atrogi | 44% | 197 | 2.54 | 6.0% |
| KAHR Medical | 34% | 194 | 2.50 | 5.9% |
| Xspray Pharma | 18% | 192 | 2.48 | 5.9% |
| Bonsai Biotherapeutics | 100% | 156 | 2.01 | 4.7% |
| Lipum | 42% | 148 | 1.91 | 4.5% |
| Xintela | 60% | 141 | 1.82 | 4.3% |
| Microbiotica | 10% | 122 | 1.57 | 3.7% |
| AnaCardio | 13% | 79 | 1.02 | 2.4% |
| Mendus | 23% | 65 | 0.84 | 2.0% |
| Geneos Therapeutics | 15% | 65 | 0.83 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 53 | 0.68 | 1.6% |
| Vitara Biomedical | 11% | 51 | 0.66 | 1.6% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 1.0% |
| Egetis Therapeutics | 1% | 22 | 0.29 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,013 | 25.99 | 61.4% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 6.2% |
| Symcel | 30% | 192 | 2.48 | 5.9% |
| Chromafora | 28% | 131 | 1.69 | 4.0% |
| Frontier Biosolutions | 2% | 26 | 0.33 | 0.8% |
| Nanologica | 44% | 15 | 0.19 | 0.5% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 565 | 7.30 | 17.2% | |
| Assets related to Portfolio companies | 236 | 3.04 | 7.2% | |
| Other assets and liabilities | 467 | 6.03 | 14.2% | |
| Net Asset Value | 3,281 | 42.36 | 100.0% | |